NCT01827384: Molecular Profiling-Based Targeted Therapy in Treating Patients With Advanced Solid Tumors

NCT01827384
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER++, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Ph+ase 2
Drug Category: Serine-Threonine Kinase Inhibitor, Tyrosine Kinase Inhibitor, Misc Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Senior)
Location of Metastases: 
Additional Notes: 
Exclusions: Patients with active brain metastases
https://ClinicalTrials.gov/show/NCT01827384

Comments are closed.

Up ↑